Copyright Reports & Markets. All rights reserved.

Global Tardive Dyskinesia (TD) Therapy Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Tardive Dyskinesia (TD) Therapy Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Tardive Dyskinesia (TD) Therapy Market Size Growth Rate by Product
      • 1.4.2 Valbenazine
      • 1.4.3 Amantadine
      • 1.4.4 Tetrabenazine
      • 1.4.5 Clonazepam
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Tardive Dyskinesia (TD) Therapy Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Tardive Dyskinesia (TD) Therapy Market Size
      • 2.1.1 Global Tardive Dyskinesia (TD) Therapy Revenue 2014-2025
      • 2.1.2 Global Tardive Dyskinesia (TD) Therapy Sales 2014-2025
    • 2.2 Tardive Dyskinesia (TD) Therapy Growth Rate by Regions
      • 2.2.1 Global Tardive Dyskinesia (TD) Therapy Sales by Regions
      • 2.2.2 Global Tardive Dyskinesia (TD) Therapy Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Tardive Dyskinesia (TD) Therapy Sales by Manufacturers
      • 3.1.1 Tardive Dyskinesia (TD) Therapy Sales by Manufacturers
      • 3.1.2 Tardive Dyskinesia (TD) Therapy Sales Market Share by Manufacturers
      • 3.1.3 Global Tardive Dyskinesia (TD) Therapy Market Concentration Ratio (CR5 and HHI)
    • 3.2 Tardive Dyskinesia (TD) Therapy Revenue by Manufacturers
      • 3.2.1 Tardive Dyskinesia (TD) Therapy Revenue by Manufacturers (2014-2019)
      • 3.2.2 Tardive Dyskinesia (TD) Therapy Revenue Share by Manufacturers (2014-2019)
    • 3.3 Tardive Dyskinesia (TD) Therapy Price by Manufacturers
    • 3.4 Tardive Dyskinesia (TD) Therapy Manufacturing Base Distribution, Product Types
      • 3.4.1 Tardive Dyskinesia (TD) Therapy Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Tardive Dyskinesia (TD) Therapy Product Type
      • 3.4.3 Date of International Manufacturers Enter into Tardive Dyskinesia (TD) Therapy Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Tardive Dyskinesia (TD) Therapy Sales by Product
    • 4.2 Global Tardive Dyskinesia (TD) Therapy Revenue by Product
    • 4.3 Tardive Dyskinesia (TD) Therapy Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Tardive Dyskinesia (TD) Therapy Breakdown Data by End User

    6 North America

    • 6.1 North America Tardive Dyskinesia (TD) Therapy by Countries
      • 6.1.1 North America Tardive Dyskinesia (TD) Therapy Sales by Countries
      • 6.1.2 North America Tardive Dyskinesia (TD) Therapy Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Tardive Dyskinesia (TD) Therapy by Product
    • 6.3 North America Tardive Dyskinesia (TD) Therapy by End User

    7 Europe

    • 7.1 Europe Tardive Dyskinesia (TD) Therapy by Countries
      • 7.1.1 Europe Tardive Dyskinesia (TD) Therapy Sales by Countries
      • 7.1.2 Europe Tardive Dyskinesia (TD) Therapy Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Tardive Dyskinesia (TD) Therapy by Product
    • 7.3 Europe Tardive Dyskinesia (TD) Therapy by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Tardive Dyskinesia (TD) Therapy by Countries
      • 8.1.1 Asia Pacific Tardive Dyskinesia (TD) Therapy Sales by Countries
      • 8.1.2 Asia Pacific Tardive Dyskinesia (TD) Therapy Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Tardive Dyskinesia (TD) Therapy by Product
    • 8.3 Asia Pacific Tardive Dyskinesia (TD) Therapy by End User

    9 Central & South America

    • 9.1 Central & South America Tardive Dyskinesia (TD) Therapy by Countries
      • 9.1.1 Central & South America Tardive Dyskinesia (TD) Therapy Sales by Countries
      • 9.1.2 Central & South America Tardive Dyskinesia (TD) Therapy Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Tardive Dyskinesia (TD) Therapy by Product
    • 9.3 Central & South America Tardive Dyskinesia (TD) Therapy by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Tardive Dyskinesia (TD) Therapy by Countries
      • 10.1.1 Middle East and Africa Tardive Dyskinesia (TD) Therapy Sales by Countries
      • 10.1.2 Middle East and Africa Tardive Dyskinesia (TD) Therapy Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Tardive Dyskinesia (TD) Therapy by Product
    • 10.3 Middle East and Africa Tardive Dyskinesia (TD) Therapy by End User

    11 Company Profiles

    • 11.1 Teva Pharma
      • 11.1.1 Teva Pharma Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Teva Pharma Tardive Dyskinesia (TD) Therapy Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Teva Pharma Tardive Dyskinesia (TD) Therapy Products Offered
      • 11.1.5 Teva Pharma Recent Development
    • 11.2 Biogen
      • 11.2.1 Biogen Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Biogen Tardive Dyskinesia (TD) Therapy Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Biogen Tardive Dyskinesia (TD) Therapy Products Offered
      • 11.2.5 Biogen Recent Development
    • 11.3 Johnson & Johnson
      • 11.3.1 Johnson & Johnson Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Johnson & Johnson Tardive Dyskinesia (TD) Therapy Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Johnson & Johnson Tardive Dyskinesia (TD) Therapy Products Offered
      • 11.3.5 Johnson & Johnson Recent Development
    • 11.4 GlaxoSmithKline
      • 11.4.1 GlaxoSmithKline Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 GlaxoSmithKline Tardive Dyskinesia (TD) Therapy Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 GlaxoSmithKline Tardive Dyskinesia (TD) Therapy Products Offered
      • 11.4.5 GlaxoSmithKline Recent Development
    • 11.5 Neurocrine Biosciences
      • 11.5.1 Neurocrine Biosciences Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Neurocrine Biosciences Tardive Dyskinesia (TD) Therapy Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Neurocrine Biosciences Tardive Dyskinesia (TD) Therapy Products Offered
      • 11.5.5 Neurocrine Biosciences Recent Development
    • 11.6 Pfizer
      • 11.6.1 Pfizer Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Pfizer Tardive Dyskinesia (TD) Therapy Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Pfizer Tardive Dyskinesia (TD) Therapy Products Offered
      • 11.6.5 Pfizer Recent Development
    • 11.7 Novartis
      • 11.7.1 Novartis Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Novartis Tardive Dyskinesia (TD) Therapy Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Novartis Tardive Dyskinesia (TD) Therapy Products Offered
      • 11.7.5 Novartis Recent Development
    • 11.8 Sanofi
      • 11.8.1 Sanofi Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Sanofi Tardive Dyskinesia (TD) Therapy Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Sanofi Tardive Dyskinesia (TD) Therapy Products Offered
      • 11.8.5 Sanofi Recent Development
    • 11.9 AstraZeneca
      • 11.9.1 AstraZeneca Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 AstraZeneca Tardive Dyskinesia (TD) Therapy Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 AstraZeneca Tardive Dyskinesia (TD) Therapy Products Offered
      • 11.9.5 AstraZeneca Recent Development
    • 11.10 Bayer AG
      • 11.10.1 Bayer AG Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Bayer AG Tardive Dyskinesia (TD) Therapy Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Bayer AG Tardive Dyskinesia (TD) Therapy Products Offered
      • 11.10.5 Bayer AG Recent Development

    12 Future Forecast

    • 12.1 Tardive Dyskinesia (TD) Therapy Market Forecast by Regions
      • 12.1.1 Global Tardive Dyskinesia (TD) Therapy Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Tardive Dyskinesia (TD) Therapy Revenue Forecast by Regions 2019-2025
    • 12.2 Tardive Dyskinesia (TD) Therapy Market Forecast by Product
      • 12.2.1 Global Tardive Dyskinesia (TD) Therapy Sales Forecast by Product 2019-2025
      • 12.2.2 Global Tardive Dyskinesia (TD) Therapy Revenue Forecast by Product 2019-2025
    • 12.3 Tardive Dyskinesia (TD) Therapy Market Forecast by End User
    • 12.4 North America Tardive Dyskinesia (TD) Therapy Forecast
    • 12.5 Europe Tardive Dyskinesia (TD) Therapy Forecast
    • 12.6 Asia Pacific Tardive Dyskinesia (TD) Therapy Forecast
    • 12.7 Central & South America Tardive Dyskinesia (TD) Therapy Forecast
    • 12.8 Middle East and Africa Tardive Dyskinesia (TD) Therapy Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Tardive Dyskinesia (TD) Therapy Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others. 
      The global Tardive Dyskinesia (TD) Therapy market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Tardive Dyskinesia (TD) Therapy market based on company, product type, end user and key regions.

      This report studies the global market size of Tardive Dyskinesia (TD) Therapy in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Tardive Dyskinesia (TD) Therapy in these regions.
      This research report categorizes the global Tardive Dyskinesia (TD) Therapy market by top players/brands, region, type and end user. This report also studies the global Tardive Dyskinesia (TD) Therapy market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Teva Pharma
      Biogen
      Johnson & Johnson
      GlaxoSmithKline
      Neurocrine Biosciences
      Pfizer
      Novartis
      Sanofi
      AstraZeneca
      Bayer AG

      Market size by Product
      Valbenazine
      Amantadine
      Tetrabenazine
      Clonazepam
      Others
      Market size by End User
      Hospitals
      Clinics
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Tardive Dyskinesia (TD) Therapy market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Tardive Dyskinesia (TD) Therapy market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Tardive Dyskinesia (TD) Therapy companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Tardive Dyskinesia (TD) Therapy submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Tardive Dyskinesia (TD) Therapy are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Tardive Dyskinesia (TD) Therapy market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now